Good ride, cowboy! Good ride!

Good ride, cowboy! Good ride!

Pam and I have had our share of hard knocks this summer. From the ongoing personal and financial trauma of our sailboat/home lightning strike to our latest bout of COVID-19, the hits just seem to keep on coming. I also (finally) finished a fictional novel, but was utterly unprepared for the hell that is getting published.

VA Continues Research on Radioligands to Optimize Treatment of mCRPC

The promising outcomes from studies of the radioligand lutetium Lu 177 vipivotide tetraxetan (Lu177-PSMA) as a second-line therapy for metastatic castration-resistant prostate cancer (mCRPC) has encouraged researchers to explore its effectiveness when moved earlier in treatment and in combination with other cancer therapies.